TJ-101 (Phrontline Biopharma)

N/A

Report date: 2025/09/23 20:00:05

Base Information

Drug NameTJ-101 (Phrontline Biopharma)
Drug Alias NameTJ-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[5] 
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-CD276DNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1CD276 antigenDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPhrontline Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSino Biopharmaceutical LtdPhrontline Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A